Anzurstobart (CC-95251, BMS-986351) is a high-affinity, fully human monoclonal anti-SIRPalpha antibody that blocks the binding of CD47 to SIRPalpha. Anzurstobart enhances macrophage phagocytic activity against DLBCL cell lines in co-culture models when combined with the antibody Rituximab (HY-P9913). Anzurstobart has the potential for solid and hematologic malignancies research.
Cross-Reactivity: <1EU/mg (<0.001EU/µg)Determined by LAL gel clotting assay
Human SIRPalpha ELISA Standard Curve. Direct ELISA binding curve demonstrating the recognition of Human Anti-Human SIRPalpha (Research Grade Anzurstobart Biosimilar) Monoclonal Antibody to SIRPalpha. The target protein was coated onto the microplate well surface, followed by binding of the antibody. Neutravidin HRP conjugate was used for detection.
* VAT and and shipping costs not included. Errors and price changes excepted
